ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.
Location: United States
Employees: 11-50
Total raised: $222M
Investors 4
| Date | Name | Website |
| - | Spur Capit... | spurcapita... |
| 10.07.2026 | Sofinnova ... | sofinnova.... |
| 10.07.2026 | B Capital ... | b.capital/ |
| 19.07.2026 | B Capital ... | bcapgroup.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.08.2025 | Series B | $132M | Omega Fund... |
| 07.12.2023 | Series A | $90M | - |
Mentions in press and media 11
| Date | Title | Description |
| 07.08.2025 | Artbio Secures $132M to Accelerate Precision Cancer Therapies | Artbio, a pioneering radiopharmaceutical firm, locked in $132 million Series B funding. This investment drives AB001, its innovative alpha radioligand therapy for metastatic castration-resistant prostate cancer, toward Phase II clinical tri... |
| 07.08.2025 | ARTBIO: $132 Million Series B Raised For New Class Of Alpha Radioligand Therapies | ARTBIO, a clinical-stage radiopharmaceutical company, is focused on developing alpha radioligand therapies (ARTs) for various types of cancer. The company has secured $132 million in Series B financing, co-led by new investors Sofinnova Inv... |
| 01.08.2025 | Top 10 Startup and Tech Funding News – Week Ending August 1, 2025 | It’s Friday, August 1, 2025, and we’re back with the top 10 startup and tech funding news stories that shaped the week. We’re a bit late hitting send today, but we’ve more than made up for it with a loaded edition—packed with some of the bo... |
| 29.07.2025 | Radiopharma-focused Artbio paints path to clinic with $132M series B | Radiopharmaceuticals-focused Artbio has drawn in a $132 million series B to push its lead prostate cancer prospect through phase 2 trials and bolster its supply chain. The round was co-led by Sofinnova Investments and B Capital, both new in... |
| 29.07.2025 | ARTBIO Raises $132M in Series B Financing | ARTBIO, a Cambridge, MA-based clinical-stage radiopharmaceutical company, raised $132M in Series B funding. The round was led by Sofinnova Investments and B Capital, along with an existing investor and participation from F-Prime, Omega Fund... |
| 01.03.2025 | Navigating the Waters of Innovation: Oncoinvent and Esmaeilzadeh Holding's Financial Journeys | In the world of finance and biotechnology, companies often find themselves at a crossroads. They must balance innovation with fiscal responsibility. Two recent reports from Oncoinvent ASA and Esmaeilzadeh Holding AB illustrate this delicate... |
| 01.03.2025 | Navigating the Waters of Change: Oncoinvent and Avida's Transformative Journeys | In the world of finance and biotechnology, change is the only constant. Two companies, Oncoinvent ASA and Avida Finans AB, recently showcased their transformative journeys in their fourth quarter and year-end reports. Both firms are navigat... |
| 27.02.2025 | Oncoinvent ASA: Fourth Quarter 2024 Update and Results | Oncoinvent ASA: Fourth Quarter 2024 Update and Results Thu, Feb 27, 2025 07:34 CET Report this content Oncoinvent ASA (OSE: ONCIN) a clinical stage 2 radiopharmaceutical company developing novel radiopharmaceutical therapies against cancer,... |
| 07.12.2023 | ARTBIO Raises $90M in Series A Financing | ARTBIO, a Cambridge, MA- and Basel, Switzerland-based clinical-stage radiopharmaceutical company, raised $90M in Series A funding. The round was led by Third Rock Ventures and an undisclosed healthcare fund. Additionally, seed lead investor... |
| 07.12.2023 | Investors pour $90M onto ARTBIO's palette less than 6 months after launching | ARTBIO launched less than six months ago with $23 million in seed funds, but in today’s dicey financing environment, there’s no better time than the present to corral new funding. The radiopharmaceutical biotech closed a $90 million series ... |
Show more